BioxyTran, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 20, 2026, disclosing a widening net loss and a significant increase in total liabilities.

Key Highlights

  • Net loss of $3,966,754 for the nine months ended September 30, 2026, compared to a net loss of $1,600,922 for the same period in 2025, according to the filing.
  • Total assets fell to $244,774 as of September 30, 2026, down from $658,552 at December 31, 2025, the company reported.
  • Total liabilities nearly doubled to $6,456,023 from $3,249,894 at December 31, 2025, the filing disclosed.
  • Cash declined to $74,369 as of September 30, 2026, from $509,914 at December 31, 2025, per the balance sheet.
  • Derivative liability increased to $1,368,347 from $403,353 at December 31, 2025, the company reported.
  • Common shares outstanding reached 114,695,220 as of November 19, 2026, up from 108,147,731 at December 31, 2025, according to the filing.
  • Total stockholders' deficit widened to $(6,211,249) as of September 30, 2026, from $(2,591,342) at December 31, 2025.

BioxyTran Financial Condition and Operating Results: Third Quarter 2026

BioxyTran, Inc. (OTCQB:BIXT), a Nevada-incorporated company based in Needham, Massachusetts, reported a net loss attributable to BioxyTran of $1,277,836 for the three months ended September 30, 2026, compared to a net loss of $282,726 for the three months ended September 30, 2025, according to the filing. For the nine-month period ended September 30, 2026, the company reported a net loss of $3,966,754, against a net loss of $1,600,922 for the comparable prior-year period. Basic and diluted loss per common share was $(0.03) for the nine months ended September 30, 2026, compared to $(0.02) for the nine months ended September 30, 2025.

Total operating expenses for the nine months ended September 30, 2026, were $2,790,184, the filing disclosed, compared to $1,235,224 for the same period in 2025. General and administrative expenses from affiliates accounted for $1,913,600 of that total for the nine-month period. Research and development expenses were $342,623 for the nine months ended September 30, 2026. The change in fair value of derivative contributed $(964,994) to other expenses for the nine-month period, compared to $(232,554) for the same period in 2025.

On the balance sheet, the company's accumulated deficit reached $(25,011,000) as of September 30, 2026, up from $(21,044,246) at December 31, 2025. The un-issued shares liability to affiliates rose sharply to $1,360,606 from $82,006 over the same period. Intangible assets, net, were $170,405 as of September 30, 2026, compared to $145,087 at December 31, 2025. The company's preferred stock stood at 43,283,991 shares issued and outstanding as of September 30, 2026, unchanged from December 31, 2025. The filing identified the company as a smaller reporting company and a non-accelerated filer.

What Was Disclosed

BioxyTran filed a Form 10-Q for the quarter ended September 30, 2026, reporting a nine-month net loss of $3,966,754, a decline in cash to $74,369, total liabilities of $6,456,023, and a total stockholders' deficit of $(6,211,249).